Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist


Like Comment
Related Content

VOLUME 114, ISSUE 4, P739-741


Jacques Donnez, M.D., Ph.D., Marie-Madeleine Dolmans, M.D., Ph.D.


Uterine fibroids are the most frequent female pelvic tumors and the most frequent indication for hysterectomy, which is associated with morbidity rates of 5% to 8%. Undertaking a myomectomy is also not free of complication and alternative treatments, such as magnetic resonance–guided focused ultrasound and uterine embolization, are often proposed (1). However, there is still a need for medical therapy with the goal to postpone or avoid surgery in women wishing to do so and in women with fibroid-related infertility (1, 2).

Read the full text here. 

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.